Submit
Search
Submit
Menu

  • Information

  • References

  • Contents

  • [1]S. C. Novick and R. P. Warrell, Jr.: Arsenicals in hematologic cancers. Semin Oncol, 27(5), 495-501 (2000)

  • [2]J. Ablain, K. Rice, H. Soilihi, A. de Reynies, S. Minucci and H. de The: Activation of a promyelocytic leukemia-tumor protein 53 axis underlies acute promyelocytic leukemia cure. Nat Med, 20(2), 167-74 (2014)

  • [3]C. H. Lee, C. L. Yu, W. T. Liao, Y. H. Kao, C. Y. Chai, G. S. Chen and H. S. Yu: Effects and interactions of low doses of arsenic and UVB on keratinocyte apoptosis. Chem Res Toxicol, 17(9), 1199-205 (2004)

  • [4]J. C. States, S. Srivastava, Y. Chen and A. Barchowsky: Arsenic and cardiovascular disease. Toxicol Sci, 107(2), 312-23 (2009)

  • [5]H. S. Yu, C. H. Lee, S. H. Jee, C. K. Ho and Y. L. Guo: Environmental and occupational skin diseases in Taiwan. J Dermatol, 28(11), 628-31 (2001)

  • [6]Mineral Commodity Summaries, February 2014. In: Ed U. S. G. Survey. (2014)

  • [7]Y. M. Hsueh, Y. L. Huang, C. C. Huang, W. L. Wu, H. M. Chen, M. H. Yang, L. C. Lue and C. J. Chen: Urinary levels of inorganic and organic arsenic metabolites among residents in an arseniasis-hyperendemic area in Taiwan. J Toxicol Environ Health A, 54(6), 431-44 (1998)

  • [8]M. M. Moore, K. Harrington-Brock and C. L. Doerr: Relative genotoxic potency of arsenic and its methylated metabolites. Mutat Res, 386(3), 279-90 (1997)

  • [9]J. P. Buchet, R. Lauwerys and H. Roels: Urinary excretion of inorganic arsenic and its metabolites after repeated ingestion of sodium metaarsenite by volunteers. Int Arch Occup Environ Health, 48(2), 111-8 (1981)

  • [10]Y. K. Huang, Y. L. Huang, Y. M. Hsueh, J. T. Wang, M. H. Yang and C. J. Chen: Changes in urinary arsenic methylation profiles in a 15-year interval after cessation of arsenic ingestion in southwest Taiwan. Environ Health Perspect, 117(12), 1860-6 (2009)

  • [11]C. Kojima, D. C. Ramirez, E. J. Tokar, S. Himeno, Z. Drobna, M. Styblo, R. P. Mason and M. P. Waalkes: Requirement of arsenic biomethylation for oxidative DNA damage. J Natl Cancer Inst, 101(24), 1670-81 (2009)

  • [12]H. S. Yu: Blackfoot disease and chronic arsenism in southern Taiwan. Int J Dermatol, 23(4), 258-60 (1984)

  • [13]H. S. Yu, G. S. Chen, H. M. Sheu, J. S. Kao, K. L. Chang and C. L. Yu: Alterations of skin-associated lymphoid tissue in the carcinogenesis of arsenical skin cancer. Proc Natl Sci Counc Repub China B, 16(1), 17-22 (1992)

  • [14]W. T. Liao, C. L. Yu, C. C. Lan, C. H. Lee, C. H. Chang, L. W. Chang, H. L. You and H. S. Yu: Differential effects of arsenic on cutaneous and systemic immunity: focusing on CD4+ cell apoptosis in patients with arsenic-induced Bowen’s disease. Carcinogenesis, 30(6), 1064-72 (2009)

  • [15]C. H. Hong, C. H. Lee, G. S. Chen, K. L. Chang and H. S. Yu: STAT3-dependent VEGF production from keratinocytes abrogates dendritic cell activation and migration by arsenic: a plausible regional mechanism of immunosuppression in arsenical cancers. Chem Biol Interact, 227, 96-103 (2015)

  • [16]K. A. Ramsey, R. E. Foong, P. D. Sly, A. N. Larcombe and G. R. Zosky: Early life arsenic exposure and acute and long-term responses to influenza A infection in mice. Environ Health Perspect, 121(10), 1187-93 (2013)

  • [17]J. A. Centeno, F. G. Mullick, L. Martinez, N. P. Page, H. Gibb, D. Longfellow, C. Thompson and E. R. Ladich: Pathology related to chronic arsenic exposure. Environ Health Perspect, 110 Suppl 5, 883-6 (2002)

  • [18]W. P. Tseng, H. M. Chu, S. W. How, J. M. Fong, C. S. Lin and S. Yeh: Prevalence of skin cancer in an endemic area of chronic arsenicism in Taiwan. J Natl Cancer Inst, 40(3), 453-63 (1968)

  • [19]S. Yeh, S. W. How and C. S. Lin: Arsenical cancer of skin. Histologic study with special reference to Bowen’s disease. Cancer, 21(2), 312-39 (1968)

  • [20]W. P. Tseng: Effects and dose--response relationships of skin cancer and blackfoot disease with arsenic. Environ Health Perspect, 19, 109-19 (1977)

  • [21]H. J. Kim, H. G. Min and E. S. Lee: Bowen’s diseases and basal cell carcinomas in a patient. J Dermatol, 26(10), 695-7 (1999)

  • [22]Y. Miki, T. Kawatsu, K. Matsuda, H. Machino and K. Kubo: Cutaneous and pulmonary cancers associated with Bowen’s disease. J Am Acad Dermatol, 6(1), 26-31 (1982)

  • [23]S. Yeh: Skin cancer in chronic arsenicism. Hum Pathol, 4(4), 469-85 (1973)

  • [24]E. Koh, N. Kondoh, H. Kaihara, H. Fujioka and K. Kitamura: Ureteral tumor with multiple Bowen’s disease forty-two years after exposure to arsenic. Eur Urol, 16(5), 398-400 (1989)

  • [25]R. C. Yu, K. H. Hsu, C. J. Chen and J. R. Froines: Arsenic methylation capacity and skin cancer. Cancer Epidemiol Biomarkers Prev, 9(11), 1259-62 (2000)

  • [26]T. Yoshida, H. Yamauchi and G. Fan Sun: Chronic health effects in people exposed to arsenic via the drinking water: dose-response relationships in review. Toxicol Appl Pharmacol, 198(3), 243-52 (2004)

  • [27]C. H. Chang, R. K. Tsai, G. S. Chen, H. S. Yu and C. Y. Chai: Expression of bcl-2, p53 and Ki-67 in arsenical skin cancers. J Cutan Pathol, 25(9), 457-62 (1998)

  • [28]T. T. Kuo, S. Hu, S. K. Lo and H. L. Chan: p53 expression and proliferative activity in Bowen’s disease with or without chronic arsenic exposure. Hum Pathol, 28(7), 786-90 (1997)

  • [29]D. Menendez, G. Mora, A. M. Salazar and P. Ostrosky-Wegman: ATM status confers sensitivity to arsenic cytotoxic effects. Mutagenesis, 16(5), 443-8 (2001)

  • [30]L. H. Yih and T. C. Lee: Arsenite induces p53 accumulation through an ATM-dependent pathway in human fibroblasts. Cancer Res, 60(22), 6346-52 (2000)

  • [31]C. H. Hsu, S. A. Yang, J. Y. Wang, H. S. Yu and S. R. Lin: Mutational spectrum of p53 gene in arsenic-related skin cancers from the blackfoot disease endemic area of Taiwan. Br J Cancer, 80(7), 1080-6 (1999)

  • [32]S. Kawara, M. Takata and K. Takehara: High frequency of DNA aneuploidy detected by DNA flow cytometry in Bowen’s disease. J Dermatol Sci, 21(1), 23-6 (1999)

  • [33]L. H. Yih, S. W. Hsueh, W. S. Luu, T. H. Chiu and T. C. Lee: Arsenite induces prominent mitotic arrest via inhibition of G2 checkpoint activation in CGL-2 cells. Carcinogenesis, 26(1), 53-63 (2005)

  • [34]L. H. Yih, Y. Y. Tseng, Y. C. Wu and T. C. Lee: Induction of centrosome amplification during arsenite-induced mitotic arrest in CGL-2 cells. Cancer Res, 66(4), 2098-106 (2006)

  • [35]W. T. Liao, K. L. Chang, C. L. Yu, G. S. Chen, L. W. Chang and H. S. Yu: Arsenic induces human keratinocyte apoptosis by the FAS/FAS ligand pathway, which correlates with alterations in nuclear factor-kappa B and activator protein-1 activity. J Invest Dermatol, 122(1), 125-9 (2004)

  • [36]M. Faris, N. Kokot, K. Latinis, S. Kasibhatla, D. R. Green, G. A. Koretzky and A. Nel: The c-Jun N-terminal kinase cascade plays a role in stress-induced apoptosis in Jurkat cells by up-regulating Fas ligand expression. J Immunol, 160(1), 134-44 (1998)

  • [37]A. Zagariya, S. Mungre, R. Lovis, M. Birrer, S. Ness, B. Thimmapaya and R. Pope: Tumor necrosis factor alpha gene regulation: enhancement of C/EBPbeta-induced activation by c-Jun. Mol Cell Biol, 18(5), 2815-24 (1998)

  • [38]C. H. Lee, W. T. Liao and H. S. Yu: Aberrant immune responses in arsenical skin cancers. Kaohsiung J Med Sci, 27(9), 396-401 (2011)

  • [39]M. Matsui, C. Nishigori, S. Toyokuni, J. Takada, M. Akaboshi, M. Ishikawa, S. Imamura and Y. Miyachi: The role of oxidative DNA damage in human arsenic carcinogenesis: detection of 8-hydroxy-2’-deoxyguanosine in arsenic-related Bowen’s disease. J Invest Dermatol, 113(1), 26-31 (1999)

  • [40]S. J. Flora: Arsenic-induced oxidative stress and its reversibility. Free Radic Biol Med, 51(2), 257-81 (2011)

  • [41]A. Barchowsky, E. J. Dudek, M. D. Treadwell and K. E. Wetterhahn: Arsenic induces oxidant stress and NF-kappa B activation in cultured aortic endothelial cells. Free Radic Biol Med, 21(6), 783-90 (1996)

  • [42]C. H. Lee, S. B. Wu, C. H. Hong, G. S. Chen, Y. H. Wei and H. S. Yu: Involvement of mtDNA damage elicited by oxidative stress in the arsenical skin cancers. J Invest Dermatol, 133(7), 1890-900 (2013)

  • [43]C. H. Lee, S. B. Wu, C. H. Hong, W. T. Liao, C. Y. Wu, G. S. Chen, Y. H. Wei and H. S. Yu: Aberrant cell proliferation by enhanced mitochondrial biogenesis via mtTFA in arsenical skin cancers. Am J Pathol, 178(5), 2066-76 (2011)

  • [44]H. K. Hamadeh, K. J. Trouba, R. P. Amin, C. A. Afshari and D. Germolec: Coordination of altered DNA repair and damage pathways in arsenite-exposed keratinocytes. Toxicol Sci, 69(2), 306-16 (2002)

  • [45]S. F. Lee-Chen, C. T. Yu and K. Y. Jan: Effect of arsenite on the DNA repair of UV-irradiated Chinese hamster ovary cells. Mutagenesis, 7(1), 51-5 (1992)

  • [46]S. Chanda, U. B. Dasgupta, D. Guhamazumder, M. Gupta, U. Chaudhuri, S. Lahiri, S. Das, N. Ghosh and D. Chatterjee: DNA hypermethylation of promoter of gene p53 and p16 in arsenic-exposed people with and without malignancy. Toxicol Sci, 89(2), 431-7 (2006)

  • [47]X. Zhou, H. Sun, T. P. Ellen, H. Chen and M. Costa: Arsenite alters global histone H3 methylation. Carcinogenesis, 29(9), 1831-6 (2008)

  • [48]T. S. Kochhar, W. Howard, S. Hoffman and L. Brammer-Carleton: Effect of trivalent and pentavalent arsenic in causing chromosome alterations in cultured Chinese hamster ovary (CHO) cells. Toxicol Lett, 84(1), 37-42 (1996)

  • [49]R. N. Huang, I. C. Ho, L. H. Yih and T. C. Lee: Sodium arsenite induces chromosome endoreduplication and inhibits protein phosphatase activity in human fibroblasts. Environ Mol Mutagen, 25(3), 188-96 (1995)

  • [50]A. Tomiyama, S. Serizawa, K. Tachibana, K. Sakurada, H. Samejima, Y. Kuchino and C. Kitanaka: Critical role for mitochondrial oxidative phosphorylation in the activation of tumor suppressors Bax and Bak. J Natl Cancer Inst, 98(20), 1462-73 (2006)

  • [51]U. E. Martinez-Outschoorn, S. Pavlides, F. Sotgia and M. P. Lisanti: Mitochondrial biogenesis drives tumor cell proliferation. Am J Pathol, 178(5), 1949-52 (2011)

  • [52]L. M. Ferreira: Cancer metabolism: the Warburg effect today. Exp Mol Pathol, 89(3), 372-80 (2010)

  • [53]C. H. Cheung, C. C. Huang, F. Y. Tsai, J. Y. Lee, S. M. Cheng, Y. C. Chang, Y. C. Huang, S. H. Chen and J. Y. Chang: Survivin - biology and potential as a therapeutic target in oncology. Onco Targets Ther, 6, 1453-62 (2013)

  • [54]F. Zhao, P. Severson, S. Pacheco, B. W. Futscher and W. T. Klimecki: Arsenic exposure induces the Warburg effect in cultured human cells. Toxicol Appl Pharmacol, 271(1), 72-7 (2013)

  • [55]F. Wang, X. Fu, X. Chen and Y. Zhao: Mitochondrial uncoupling inhibits p53 mitochondrial translocation in TPA-challenged skin epidermal JB6 cells. PloS one, 5(10), e13459 (2010)

  • [56]Y. P. Lin, B. Z. Zhu, M. C. Yang, B. Frei, M. H. Pan, J. K. Lin and Y. J. Wang: Bcl-2 overexpression inhibits tetrachlorohydroquinone-induced apoptosis in NIH3T3 cells: a possible mechanism for tumor promotion. Mol Carcinog, 40(1), 24-33 (2004)

  • [57]E. Samper, L. Morgado, J. C. Estrada, A. Bernad, A. Hubbard, S. Cadenas and S. Melov: Increase in mitochondrial biogenesis, oxidative stress, and glycolysis in murine lymphomas. Free Radic Biol Med, 46(3), 387-96 (2009)

  • [58]C. H. Ussakli, A. Ebaee, J. Binkley, T. A. Brentnall, M. J. Emond, P. S. Rabinovitch and R. A. Risques: Mitochondria and tumor progression in ulcerative colitis. J Natl Cancer Inst, 105(16), 1239-48 (2013)

  • [59]U. Martinez-Outschoorn, F. Sotgia and M. P. Lisanti: Tumor microenvironment and metabolic synergy in breast cancers: critical importance of mitochondrial fuels and function. Semin Oncol, 41(2), 195-216 (2014)

  • [60]D. Martins, F. F. Beca, B. Sousa, F. Baltazar, J. Paredes and F. Schmitt: Loss of caveolin-1 and gain of MCT4 expression in the tumor stroma: key events in the progression from an in situ to an invasive breast carcinoma. Cell Cycle, 12(16), 2684-90 (2013)

  • [61]R. Jitschin, A. D. Hofmann, H. Bruns, A. Giessl, J. Bricks, J. Berger, D. Saul, M. J. Eckart, A. Mackensen and D. Mougiakakos: Mitochondrial metabolism contributes to oxidative stress and reveals therapeutic targets in chronic lymphocytic leukemia. Blood, 123(17), 2663-72 (2014)

  • [62]E. Macias, D. Rao, S. Carbajal, K. Kiguchi and J. DiGiovanni: Stat3 binds to mtDNA and regulates mitochondrial gene expression in keratinocytes. J Invest Dermatol, 134(7), 1971-80 (2014)

  • [63]J. Permuth-Wey, Y. A. Chen, Y. Y. Tsai, Z. Chen, X. Qu, J. M. Lancaster, H. Stockwell, G. Dagne, E. Iversen, H. Risch, J. Barnholtz-Sloan, J. M. Cunningham, R. A. Vierkant, B. L. Fridley, R. Sutphen, J. McLaughlin, S. A. Narod, E. L. Goode, J. M. Schildkraut, D. Fenstermacher, C. M. Phelan and T. A. Sellers: Inherited variants in mitochondrial biogenesis genes may influence epithelial ovarian cancer risk. Cancer Epidemiol Biomarkers Prev, 20(6), 1131-45 (2011)

  • [64]G. Wen, G. M. Calaf, M. A. Partridge, C. Echiburu-Chau, Y. Zhao, S. Huang, Y. Chai, B. Li, B. Hu and T. K. Hei: Neoplastic transformation of human small airway epithelial cells induced by arsenic. Mol Med, 14(1-2), 2-10 (2008)

  • [65]C. V. Dang: MYC, metabolism, cell growth, and tumorigenesis. Cold Spring Harb Perspect Med, 3(8) (2013)

  • [66]F. Li, Y. Wang, K. I. Zeller, J. J. Potter, D. R. Wonsey, K. A. O’Donnell, J. W. Kim, J. T. Yustein, L. A. Lee and C. V. Dang: Myc stimulates nuclearly encoded mitochondrial genes and mitochondrial biogenesis. Mol Cell Biol, 25(14), 6225-34 (2005)

  • [67]J. Kim, J. H. Lee and V. R. Iyer: Global identification of Myc target genes reveals its direct role in mitochondrial biogenesis and its E-box usage in vivo. PloS one, 3(3), e1798 (2008)

  • [68]L. W. Finley, A. Carracedo, J. Lee, A. Souza, A. Egia, J. Zhang, J. Teruya-Feldstein, P. I. Moreira, S. M. Cardoso, C. B. Clish, P. P. Pandolfi and M. C. Haigis: SIRT3 opposes reprogramming of cancer cell metabolism through HIF1alpha destabilization. Cancer Cell, 19(3), 416-28 (2011)

  • [69]T. Zhang, Y. Qi, M. Liao, M. Xu, K. A. Bower, J. A. Frank, H. M. Shen, J. Luo, X. Shi and G. Chen: Autophagy is a cell self-protective mechanism against arsenic-induced cell transformation. Toxicol Sci, 130(2), 298-308 (2012)

  • [70]C. U. Lago, S. M. Nowinski, J. E. Rundhaug, M. E. Pfeiffer, K. Kiguchi, K. Hirasaka, X. Yang, E. M. Abramson, S. B. Bratton, O. Rho, R. Colavitti, M. A. Kenaston, T. Nikawa, C. Trempus, J. Digiovanni, S. M. Fischer and E. M. Mills: Mitochondrial respiratory uncoupling promotes keratinocyte differentiation and blocks skin carcinogenesis. Oncogene, 31(44), 4725-31 (2012)

  • [71]K. P. Singh, R. Kumari, J. Treas and J. W. DuMond: Chronic exposure to arsenic causes increased cell survival, DNA damage, and increased expression of mitochondrial transcription factor A (mtTFA) in human prostate epithelial cells. Chem Res Toxicol, 24(3), 340-9 (2011)

  • [72]H. Naranmandura, S. Xu, T. Sawata, W. H. Hao, H. Liu, N. Bu, Y. Ogra, Y. J. Lou and N. Suzuki: Mitochondria are the main target organelle for trivalent monomethylarsonous acid (MMA (III))-induced cytotoxicity. Chem Res Toxicol, 24(7), 1094-103 (2011)

Article Metrics

  • Information

  • Download

  • Contents

Frontiers in Bioscience-Scholar (FBS) is published by IMR Press from Volume 13 Issue 1 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

1 Jun 2016Review

Role of mitochondria, ROS, and DNA damage in arsenic induced carcinogenesis

Chih-Hung Lee 1, Hsin-Su Yu 2,3,*
Affiliations
Article Info

1 Department of Dermatology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan

2 Department of Dermatology, Kaohsiung Medical University, Kaohsiung, Taiwan

3 National Environmental Research Center, National Health Research Institutes, Zhunan, Taiwan

*Author to whom correspondence should be addressed.

 

Abstract

The International Agency for Research on Cancer (IARC) declared arsenic a class I carcinogen. Arsenic exposure induces several forms of human cancers, including cancers of skin, lung, liver, and urinary bladder. The majority of the arsenic-induced cancers occur in skin. Among these, the most common is Bowen’s disease, characterized by epidermal hyperplasia, full layer epidermal dysplasia, leading to intraepidermal carcinoma as well as apoptosis, and moderate dermal infiltrates, which require the participation of mitochondria. The exact mechanism underlying arsenic induced carcinogenesis remains unclear, although increased reactive oxidative stresses, leading to chromosome abnormalities and uncontrolled growth, and aberrant immune regulations might be involved. Here, we highlight how increased mitochondrial biogenesis and oxidative stress lead to mitochondrial DNA damage and mutation in arsenic induced cancers. We also provide therapeutic rationale for targeting mitochondria in the treatment of arsenic induced cancers.

Keywords

  • Arsenic
  • Mitochondria
  • ROS
  • DNA Damages
  • Carcinogenesis
  • Review

References